Dr. Moore On Safety Profile Of Mirvetuximab Soravtansine In Ovarian Cancer

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

Dr. Gilbert on the Safety Profile of Mirvetuximab Soravtansine/Bevacizumab in Ovarian Cancer

Dr. Moore on Benefit of Mirvetuximab Soravtansine in Patients With Ovarian Cancer

Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian Cancer

Targeted Oncology

An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian Cancer

Targeted Oncology

Dr. English on Mirvetuximab Soravtansine in Ovarian Cancer

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

Mirvetuximab Soravtansine: The SORAYA & MIRASOL Studies. The future of Targeting FRα

Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer

Targeted Oncology

PARP Inhibitors in Ovarian Cancer: Safety Profile

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian Cancer

Dr. Moore on the Prevalence of Ovarian Cancer

Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian Cancer

Targeted Oncology

Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian Cancer

Targeted Oncology

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

Dr. Moore on the NOVA Trial for Ovarian Cancer

Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian Cancer